• 1
    Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet (2003) 362 15271535.
  • 2
    Mac Mahon S., Peto R., Cutler J. et al. Blood pressure, stroke, and coronary heart disease; part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 335 765774.
  • 3
    Staessen J.A., Wang J.G., Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens. (2003) 2 10551076.
  • 4
    Egger M., Smith G.D. Meta-analysis bias in location and selection of studies. BMJ (1998) 316 6166.
  • 5
    Dahlöf B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet (2002) 359 9951003.
  • 6
    Brunner H.R., Gavras H. Angiotensin blockade for hypertension: a promise fulfilled. Lancet (2002) 359 990992.
  • 7
    Belz G.G. Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology. Br. J. Clin. Pharmacol. (2003) 56 310.
  • 8
    Mancia G. Clinical differences among angiotensin II receptor antagonists. Blood Press. (2001) 2(Suppl.) 1924.
  • 9
    Meredith P.A. Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers. Blood Press. (2001) 3(Suppl.) 1117.
  • 10
    Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet (1998) 351 17551762.
  • 11
    Elmfeldt D., Olofsson B., Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press. (2002) 11 293301.
  • 12
    Gradman A.H. AT (1)-receptor blockers: differences that matter. J. Hum. Hypertens. (2002) 16(Suppl. 3) S9S16.
  • 13
    Oparil S., Dyke S., Harris F. et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin. Ther. (1996) 18 797810.
  • 14
    Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet (2000) 355 637645.
  • 15
    Hansson L. The relationship between dose and antihypertensive effect for different AT1-receptor blockers. Blood Press. (2001) 10(Suppl. 3) 3339.
  • 16
    Hobbs F.D.R., Irwin P., Rubner J. Evidence-based treatment of hypertension: what's the role of angiotensin II receptor blockers? Br. J. Cardiol. (2005) 12 6570.
  • 17
    Brousil J.A., Burke J.M. Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin. Ther. (2003) 25 10411055.
  • 18
    Whittaker A. A review of olmesartan medoxomil: a new angiotensin II receptor blocker. Br. J. Cardiol. (2005) 12 125129.
  • 19
    Nies A.S. Principles of therapeutics, in: Goodman and Gilman's. The pharmacological basis of therapeutics, 10th edn., McGraw-Hill Press, New York, 2001, pp. 4566.
  • 20
    European Medicines Agency – Committee for Medicinal Products for Human Use. Note for guidance on clinical investigation of medicinal products in the treatment of hypertension, 2004. EMEA. CPMP/EWP/238/95 Rev. 2. London, 23 June.
  • 21
    Brunner H.R., Menard J., Waeber B. et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J. Hypertens. (1990) 8 311.
  • 22
    Oates J.A., Brown N. Antihypertensive agents and the drug therapy of hypertension, in: HardmanJ.G., LimbirdL.E. (Eds), Goodman and Gilman's. The pharmacological basis of therapeutics, 10th edn., McGraw-Hill Press, New York, 2001.
  • 23
    Püchler K., Laies P., Stumpe K.O. Blood pressure response, but no adverse event incidence, correlates with dose of angiotensin II antagonist. J. Hypertens. (2001) 19(Suppl. 1) S41S48.
  • 24
    Reif M., White W.B., Fagan T.C. et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am. J. Cardiol. (1998) 82 961965.
  • 25
    Reeves R.A., Lin C.S., Kassler-Taub K., Pouleur H. Dose-related efficacy of irbesartan for hypertension. An integrated analysis. Hypertension (1998) 31 13111316.
  • 26
    Gradman A.H., Arcuri K.E., Goldberg A.I. et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension (1995) 25 13451350.
  • 27
    Stumpe K.O., Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J. Hum. Hypertens. (2002) 16(Suppl. 2) S24S28.
  • 28
    Oparil S., Williams D., Chrysant S., Marbury T., Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J. Clin. Hypertens. (2001) 3 283291, 318.
  • 29
    Brunner H.R., Stumpe K.O., Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin. Drug Invest. (2003) 23 419430.
  • 30
    Smith D., Dubiel R., Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan and irbesartan. Am. J. Cardiovacs. Drugs (2005) 5 4150.
  • 31
    Norwood D., Branch E., Smith B., Honeywell M. Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast. (2002) 27 611618.
  • 32
    Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am. J. Hypertens. (2000) 13 (Suppl 1) 18S24S.
  • 33
    Stumpe K.O. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin. Ther. (2004) 26(Suppl. A) A33A37.
  • 34
    Julius S., Kjeldsen S., Weber M. et al. for the Value trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet (2004) 363 20222031.
  • 35
    Whelton P.K. Epidemiology and the prevention of hypertension. J. Clin. Hypertens. (2004) 6 636642.
  • 36
    Cook N.R., Cohen J., Hebert P.R., Taylor J.O., Hennekens C.H. Implications of small reductions in diastolic blood pressure for primary prevention. Arch. Intern. Med. (1995) 155 701709.
  • 37
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension; final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA (1991) 2645 32553264.
  • 38
    Poulter N.R., Wedel H., Dahlöf B. et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet (2005) 366 907913.